[Efficacy and safety assessment program of fusafungin in the treatment of acute upper respiratory tract infections in adults (PROFIL): multicenter study in Poland].
The aim of the study was evaluation of efficacy and safety of new form of fusafungine in the treatment of upper respiratory tract infections in adults. The study comprised 1639 patients treated in 288 centres in Poland. Fusafungine (Bioparox) was administered 4 applications to the pharynx and/or to the nose every 4 hours during the day. The result of treatment were observed after 5 days. Signs and symptoms of infections were observed both by the physician and by the patients. In 1188 patients regression of signs and symptoms was observed after 5 days of treatment both in bacterial and viral infections. Fusafungine in a new (without freon) form is efficacy and safety drugs in the treatment of upper respiratory tract infections in adults.
Jurkiewicz
Dariusz
D
Klinika Otolaryngologii CSK WAM w Warszawie. djurkiewicz@lekarz.net
Ochwat
Agnieszka
A
D000208:Acute Disease; D000328:Adult; D000336:Aerosols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D047630:Depsipeptides; D003937:Diagnosis, Differential; D004333:Drug Administration Routes; D005260:Female; D005670:Fusarium; D006801:Humans; D008297:Male; D011044:Poland / Q000453:epidemiology; D015397:Program Evaluation; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D012720:Severity of Illness Index
D000336:Aerosols; D000900:Anti-Bacterial Agents; D047630:Depsipeptides; C014001:fusafungin